Japanese journal of ophthalmology · 2026
Incidence and risk factors related to ocular adverse effects caused by S-1 chemotherapy.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kamao Tomoyuki, Yamada Masakazu, Shiraishi Atsushi, Sakai Jo, Ohashi Yuichi, TS-1 study working group
Аннотация
PURPOSE: This study aimed to identify the incidence and risk factors of corneal disorders (CDs) and lacrimal passage obstruction (LPO) caused by S-1 chemotherapy.
STUDY DESIGN: Multicenter prospective cohort study.
METHODS: This study included patients who were administered S-1 for the first time and underwent ophthalmic evaluations for 1 year during the treatment. CD was defined as an increase of >2 points in the National Eye Institute classification. LPO was defined as an abnormality in lacrimal irrigation. Risk factors were identified via univariate and multivariate analyses.
RESULTS: This study enrolled 126 men and 49 women with a mean age of 68.1 (30-87) years. Over a mean follow-up of 169.6 ± 127.3 days, the incidence rates of CD and LPO were 24.6% and 14.0%, with 1-year cumulative incidence rates of 37.0% and 25.9%, respectively. The risk factors for CD were no previous use of eye drops (hazard ratio [HR] 3.45, p = 0.0955) and tear breakup time over 5 s prior to S-1 chemotherapy (HR 1.86, p = 0.0535). The risk factors for LPO were male sex (HR 5.00, p = 0.0311), primary tumor other than gastric cancer (HR 2.27, p = 0.0666), previous use of eye drops for dry eye (HR 21.16, p = 0.0035), and previous visual disturbance (HR 2.89, p = 0.0303).
CONCLUSION: The high incidence of CD and LPO among patients undergoing S-1 chemotherapy warrants close monitoring of those with identified risk factors, especially within the first six months of chemotherapy.
STUDY DESIGN: Multicenter prospective cohort study.
METHODS: This study included patients who were administered S-1 for the first time and underwent ophthalmic evaluations for 1 year during the treatment. CD was defined as an increase of >2 points in the National Eye Institute classification. LPO was defined as an abnormality in lacrimal irrigation. Risk factors were identified via univariate and multivariate analyses.
RESULTS: This study enrolled 126 men and 49 women with a mean age of 68.1 (30-87) years. Over a mean follow-up of 169.6 ± 127.3 days, the incidence rates of CD and LPO were 24.6% and 14.0%, with 1-year cumulative incidence rates of 37.0% and 25.9%, respectively. The risk factors for CD were no previous use of eye drops (hazard ratio [HR] 3.45, p = 0.0955) and tear breakup time over 5 s prior to S-1 chemotherapy (HR 1.86, p = 0.0535). The risk factors for LPO were male sex (HR 5.00, p = 0.0311), primary tumor other than gastric cancer (HR 2.27, p = 0.0666), previous use of eye drops for dry eye (HR 21.16, p = 0.0035), and previous visual disturbance (HR 2.89, p = 0.0303).
CONCLUSION: The high incidence of CD and LPO among patients undergoing S-1 chemotherapy warrants close monitoring of those with identified risk factors, especially within the first six months of chemotherapy.